Eloquent AI | $7,400,000 | (Sep 12, 2025)
Meela Inc. | $3,500,000 | (Sep 12, 2025)
TrustNXT | $1,874,888 | (Sep 12, 2025)
Actithera
Norway
- Oslo
- 09/07/2025
- Series A
- $75,500,000
Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, and seed investors M Ventures, and Arkin Bio Ventures II, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is committed to advancing a differentiated pipeline addressing critical unmet needs in oncology.
- Industry Biotechnology Research
- Website https://actithera.com/
- LinkedIn https://www.linkedin.com/company/actithera/
Related People
Andreas GoutopoulosFounder
United States -
Boston, Massachusetts
Founder of Actithera, developing smarter radiopharmaceuticals to treat cancer more effectively and safely. Focused on turning chemistry and science into better outcomes for patients.
Kriya Therapeutics, Inc. | $320,000,000 | (Sep 12, 2025)
Goodpath | $18,000,000 | (Sep 12, 2025)
BacAlt | $2,037,362 | (Sep 12, 2025)
Quack AI | $7,000,000 | (Sep 12, 2025)
Diana Health (We're Hiring!) | $55,000,000 | (Sep 12, 2025)
OpenHealth Technologies | $3,000,000 | (Sep 12, 2025)
Brain Co. | $30,000,000 | (Sep 12, 2025)
AegisAI Security | $13,000,000 | (Sep 12, 2025)
Clyx | $14,000,000 | (Sep 12, 2025)